The eISF, or electronic Investigator Site File, is the digital version of the paper-based investigator site file (ISF). It enables the collection in digital form of essential documents that demonstrate a clinical trial was conducted in accordance with Good Clinical Practice (GCP) guidelines, as well as regulatory and sponsor requirements. These documents include the protocol, informed consent forms, study reports, lab results, and other documentation related to the trial.
Leads to this page The use of eISFs has several advantages over paper-based ISFs :
• efficiency in document management
• increases accuracy and completeness of data
• enhances security of sensitive information
• facilitates remote monitoring of study sites
• real-time data access and sharing between sites, sponsors, and regulatory agencies
Theuse of eISFs represents a significant step forward in the conduct of clinical research, enabling faster and more efficient trial management while ensuring compliance with regulatory and ethical standards.
June 26, 2025
June 30 – 4:00 PM to 5:15 PM (CET) xShare, an EU-funded project, strengthens procurement capabilities in digital health by translating the European Electronic Health Record Exchange Format (EEHRxF) into concrete requirements for tenders. This inaugural webinar presents key EU rules and promotes the procurement of interoperable solutions. It aims to raise awareness, share innovative […]
June 26, 2025
June 25–27 – JETRO – Japan External Trade Organization Pavilion – Osaka Booth Hall 6‑A, A‑0408 Philippe Haran – MD, is representing Telemedicine Technologies at the Japan Health Exhibition 2025, as a guest of Micron, Inc., a valued member of our CROAlliance partner. At Micron’s booth, he’s engaging with healthcare leaders and exploring collaboration opportunities […]
June 26, 2025
Applied Clinical Trials Online At a time when artificial intelligence (AI) is redefining industries at an unprecedented pace, the pharmaceutical sector stands on the brink of a progressive transformation. AI is not just a tool but a catalyst that promises to accelerate drug development timelines in ways we’ve never seen before. However, the true potential […]